# Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

> **NCT01820806** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 100 mg dose of [14C] GLPG0634

## Key facts

- **NCT ID:** NCT01820806
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2013-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820806, "Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01820806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*